BioLab Holdings Launches EmeraNova™ to Advance the Future of Tissue Healing
Phoenix — BioLab Holdings today announced a broader mission with the launch of EmeraNova™, a new company identity reflecting its wider ambition to advance tissue healing across specialities, stages of healing and care settings. The launch marks the company’s effort to build a global platform focused on identifying promising technologies and accelerating their adoption in clinical practice.
EmeraNova aims to develop emerging and novel technologies—“Emer” and “Nova”—by building an expanding suite of tissue-healing solutions, world-class support, and ways to bring together expert perspectives and clinical insights that can help shape the future. The company’s roots in chronic wound care will underpin its direction in tissue healing, while it continues to supply its amniotic membrane product portfolio.
“BioLab was founded on a commitment to improving patients’ quality of life,” said Jaime Leija, President and Chief Executive Officer of EmeraNova. “With EmeraNova, we are broadening that perspective. We are exploring technologies around the world and considering how different solutions, specialities and clinical insights can work together to create a more integrated care ecosystem. This broader perspective allows us to build on previous achievements while bringing appropriate innovations more quickly to healthcare professionals and the patients they serve.”
The company’s expanding solutions model reflects its main product areas: Assessment and Differentiation, Diagnosis, Wound Cleansing, Control, Preparation, Healing and Regeneration, Reassessment, and Tissue Remodelling. Through these categories, EmeraNova is seeking partners worldwide to bring promising technologies to market quickly and equip healthcare professionals with advanced and effective solutions.
“As part of BioLab, we have built our reputation in advanced wound-care products,” said Scott Swonger, Chief Transformation Officer of EmeraNova. “EmeraNova represents a more comprehensive approach, founded on the belief that tissue healing is a continuous process involving ongoing dialogue, partnerships and improvements to the resources available to healthcare professionals.”
To fulfil its mission of reaching more patients, EmeraNova aims to enter new healthcare settings, including acute care and hospital outpatient departments (HOPDs), while continuing to improve and advance service delivery in outpatient clinics and mobile wound-care clinics. The company expects to broaden its clinical applications in surgery, sports medicine, vascular care and aesthetics, and to expand its innovations worldwide through international commercialisation partnerships.
EmeraNova’s commitment to helping shape the future of tissue healing is reflected in ongoing multi-product clinical research. In 2026 alone, the company has conducted four clinical trials and published three retrospective studies reviewed by its peers.
EmeraNova will introduce its new brand and mission at the Symposium for Advanced Wound Care (SAWC) in Las Vegas this weekend, 16–18 October. Interested parties can visit stand 241 to learn more about EmeraNova’s tissue-healing technologies.
For more information about EmeraNova, its solutions and products, visit emeranova.com.
EmeraNova
EmeraNova™ is a Phoenix-based medical technology company focused on advancing tissue healing. Through a practitioner-led product strategy, entrepreneurial partnerships and rapid commercialisation, EmeraNova identifies, develops and brings technologies to market across healthcare settings. BLS Labs, LLC and BLS Sales & Marketing, LLC are accredited by the Association for Advancing Tissue and Biologics (AATB), reflecting the company’s commitment to stringent standards for quality, safety and operational excellence.
Source: jawawa.id (https://jawawa.id/newsitem/biolab-holdings-launches-emeranova-tm-to-advance-the-future-of-tissue-healing-1792194630)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5792681/biolab-holdings-luncurkan-emeranova-untuk-mengembangkan-masa-depan-pemulihan-jaringan), translated from Indonesian